Trials for Sutent and lung cancer candidate figitumumab fail in phase III
Will work with Cellzome on targets to regulate epigenetics and immuno-inflammatory diseases
PROMs could inform health service decision-making at all levels, says new report
To assemble an orphan and rare disease marketing brand you’ll need a versatile toolkit, says MSI’s Michael Craig
Featured Appointment
Teva Pharmaceutical Industries has appointed Dr Phillip Frost as chairman of the board of directors.
His appointment is part of a reshuffle...
Service Company News
Service Search
Featured Event
27/04/2010 - 29/04/2010 -
Barcelona,
